SecBot SecBot
PRESS-RELEASE ·Filed Nov 3, 2026

PHG

Royal Philips
NEUTRAL
Impact 5/10
Horizonweeks Processed14d 1h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor finalization of the DOJ settlement documentation and any further developments in other Respironics-related proceedings. The reiterated guidance and strong order intake suggest stable near-term performance, but the macro environment and tariff uncertainties remain key watchpoints.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$28.46
T+0 close · Nov 3, 2026 · via day close
Latest settled
+6.85%
T+5 · $30.41 · next T+20 in 15d
Vs SPY
+7.44%
α at T+5
Latest observation
+7.47%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $28.46entry
  2. T+1 · 13d ago +9.14%α +7.48% · $31.06
  3. T+5 · 7d ago +6.85%α +7.44% · $30.41
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Philips reported Q3 2026 comparable sales growth of 3% and adjusted EBITA margin expansion of 70 bps to 13.0%, while reiterating full-year 2026 guidance. The company also recorded a EUR 288 million provision for a Respironics DOJ settlement agreement in principle, which is expected to be paid in Q1 2027.

Key Financial Metrics

Guidance
3%-4.5% comparable sales growth
maintained
Free Cash Flow
$384.0M

Key Facts

  • Comparable order intake grew 8% in Q3 2026, driven by Diagnosis & Treatment.
  • Comparable sales increased 3% to EUR 4.4 billion.
  • Adjusted EBITA margin improved 70 bps to 13.0%.
  • Operating cash flow was EUR 544 million; free cash flow was EUR 384 million.
  • Philips reiterated full-year 2026 outlook: comparable sales growth 3%-4.5%, adjusted EBITA margin 13.5%-14.0%, free cash flow EUR 1.5-1.7 billion.
  • Recorded a EUR 288 million provision for Respironics DOJ settlement in principle; payment expected Q1 2027.
  • Issued EUR 650 million green bonds under the EU Green Bond Standard.
  • Productivity program delivered EUR 170 million net savings in Q3, EUR 427 million year-to-date.

Financial Impact

EUR 288 million provision for DOJ settlement; EUR 650 million green bond issuance; EUR 384 million free cash flow in Q3.

revenueebitdacash flowdebt

Segment Breakdown

SegmentGrowth
Diagnosis & Treatment0.0%
Connected Care+5.0%
Personal Health+8.0%

Risk Factors

  • DOJ settlement finalization and payment in Q1 2027 could impact cash flow.
  • Ongoing Respironics-related investigations by US State Attorneys General remain unresolved.
  • Macroeconomic and tariff uncertainties may affect full-year outlook achievement.
  • China sales decline in Precision Diagnosis segment may persist.

Market Snapshot

Exchange
NYSE
Sector
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Analyst Consensus
52% bullish (29 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3393896

US Market Status

Market Closed · Opens in 7h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026